Table 5.
Publication bias analysis.
| IBD | Non-IBD | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Outcome | No. of articles | Cumulative incidence | 95% CI | P of Egger's test | No. of articles | Cumulative incidence | 95% CI | P of Egger's test | RR | 95% CI of RR | P of RR |
| TLI | |||||||||||
| Original data | 54 | 11.2% | 8.1–14.7% | 0.604 | 235 | 9.2% | 8.1–10.3% | <0.001 | 1.22 | 0.88–1.68 | 0.224 |
| After trim-and-fill | 54 | 11.2% | 8.1–14.7% | 0.604 | 318 | 3% | 2.3–3.8% | 0.256 | 3.76 | 2.54–5.55 | <0.001 |
| MTX-D | |||||||||||
| Original data | 39 | 2.6% | 1.8- 3.6% | 0.775 | 139 | 1.8% | 1.3–2.3% | <0.001 | 1.48 | 0.94–2.33 | 0.089 |
| After trim-and-fill | 43 | 3.3% | 2.2–4.4% | 0.852 | 166 | 0.7% | 0.3–1.1% | 0.662 | 5 | 2.51–9.98 | <0.001 |
| LF | |||||||||||
| Original data | 9 | 3.6% | 1.3–6.7% | NA | 32 | 3.7% | 2.5–5.2% | <0.001 | 0.96 | 0.39–2.35 | 0.933 |
| After trim-and-fill | 10 | 3.1% | 1.1–5.9% | 0.735 | 46 | 0.1% | 0–0.6% | 0.719 | 38.62 | 4.17–357.94 | 0.001 |
IBD, inflammatory bowel disease; CI, confidence interval; RR, relative risk; TLI, total liver injury; MTX-D, methotrexate discontinuation; LF, liver fibrosis; NA, not available due to limited number of articles (<10).